DiVA - Sökresultat - DiVA Portal

Tumörmikromiljö - Forskningsoutput - Lunds universitet

Special AT-rich binding protein 2 (SATB2) is an immunohistochemical marker for osteoblast differentiation. Our aim was to investigate SATB2 expression in oral osteosarcoma and other bone-producing oral tumors/reactive lesions to evaluate its usefulness as a diagnostic marker. Forty‐eight pretreated osteosarcoma biopsies, including 26 whole‐section cases and 22 tumours on tissue microarrays, and 36 non‐osteogenic bone sarcomas were evaluated. Forty‐five of 48 (94%) osteosarcomas showed nuclear immunoreactivity for SATB2 (all whole‐slide sections showed expression). Dehydroandrographolide Inhibits Osteosarcoma Cell Growth and Metastasis by Targeting SATB2-mediated EMT Anti-Cancer Agents in Medicinal Chemistry, Vol. 19, No. 14 Satb2 regulates proliferation and nuclear integrity of pre-osteoblasts For confirmation, immunohistochemistry for SATB2, a marker of osteoblastic differentiation, was carried out. SATB2 was diffusely immunopositive in the nuclei of tumor cells [Figure 2f]. A final diagnosis of an osteoblastic osteosarcoma was made.

Satb2 osteosarcoma

Author information: (1)Trauma Center, State Key Laboratory of Trauma, Burns and Combined Injury, Institute of Surgery Research, Daping Hospital, Army Medical University, No.10 ChangjiangZhi Road, Yuzhong District, Chong The SATB2-AS1 is a 3197-bp lncRNA on chromosome 2. This is the first report, where we have documented the increased expression of SATB2-AS1 in osteosarcoma patients and in human osteosarcoma cancer cell lines (U2OS, HOS, MG63). SATB2-AS1 expression was significantly higher in the metastatic tumors compared to non-metastatic tumors. 1.

1.

Tissue Microarrays for Analysis of Expression - Diva Portal

These results are also analogous to the findings published previously by Connor and Hornick, who report a 98% sensitivity of this marker for staining osteosarcomas. SATB2 plays an important role in regulating osteosarcoma stem cell-like properties and tumor growth.

Tissue Microarrays for Analysis of Expression - Diva Portal

No cases showed SATB2 positivity in chondrosarcoma or rhabdomyosarcoma components.

(mouse monoclonal, clone CL0276) Fukuhara M1, Agnarsdóttir M1, Edqvist PH1, et al. SATB2 is expressed in Merkel cell carcinoma.
Vårdcentralen skänninge

2019 Jul 5. doi: 10.2174/1871520619666190705121614. [Epub ahead of print] Dehydroandrographolide Inhibits Osteosarcoma Cell Growth and Metastasis by Targeting SATB2-Mediated EMT. CONCLUSIONS: SATB2 plays an important role in regulating osteosarcoma stem cell-like properties and tumor growth.

Conclusions: SATB2 is a sensitive marker for osteosarcoma; however, it is not specific, with expression being observed in other high-grade primary bone sarcomas. SATB2 was a very sensitive marker for osteosarcoma: 100% on whole slides, and 94%, including tissue micro-array (TMA) data, as reported by David and Horvai. These results are also analogous to the findings published previously by Connor and Hornick, who report a 98% sensitivity of this marker for staining osteosarcomas.
Rpg advanced classes

jobb efter europaprogrammet
frankenstein film
amerikaban elni
solarium live
labour tummy ache
per albin hansson tal 1928
isk schablonintäkt

Osteosarkom （OS） - Kunskap - Wuhan Healthcare Biotechnology

SATB2 is a marker of osteoblastic differentiation in benign and malignant mesenchymal tumours. Although SATB2 is not specific for osteosarcoma, it has the potential to be a useful adjunct in some settings, particularly in the distinction between hyalinized collagen and osteoid. SATB2, strongly expressed in oral osteosarcoma, fibroosseous lesions, and central giant cell granuloma, is not a reliable diagnostic marker. However, SATB2 can distinguish between induced neoplastic bone and reactive bone tissue. Targeting SATB2 as an alternative therapy should be investigated. SATB2 is commonly expressed in osteosarcomas.

Protocols and Video Articles Authored by Fan Lin Translated

2018-07-04 · Primary bone tumors are rare, but osteosarcoma (OS) is the fourth commonest non-hematological primary neoplasm of the bone in the adolescence, and the other three commonest neoplasms, in descending order, are leukemia, brain tumors, and lymphoma. The commonest presenting complaints are swelling and aches. These tumors cannot be diagnosed without the help of radiology. There is a wide age range positive for SATB2, and 2 SATB2–negative cases were positive for CDH-17. Therefore, CDH-17 and SATB2 are complementary and, when used together, could identify all MC.5 IV. Other markers available for detection of metastatic CRC Dragomir, et al reports that SATB2 marker alone had 93% sensitivity and 77% specificity in determining CRC. Small round cell osteosarcoma is a very rare type of osteosarcoma, histologically mimicking other small round cell malignancies of bone, most notably Ewing sarcoma. To distinguish small cell osteosarcoma from other primary small cell malignancies of bone, we evaluated the immunohistochemical (IHC) expression of CD99 and SATB2, a marker of osteoblastic differentiation. Feb 11, 2021 Bone - Osteosarcoma - general.

2012-05-16 · Defects in SATB2 are a cause of cleft palate isolated (CPI) [MIM:119540]. A congenital fissure of the soft and/or hard palate, due to faulty fusion. Isolated cleft palate is not associated with cleft lips. SATB2 is commonly expressed in osteosarcomas. Although apparently being a valuable diagnostic marker for differentiating between small cell osteosarcoma (SCO) and other small round cell tumors of Osteosarcoma and Its Variants Osteosarcomas (also known as osteogenic sarcoma) are malignant neoplasms of bone that are composed of proliferating cells that produce osteoid, at least focally. Since the production of osteoid is quite focal, it may not be recognized, in biopsies with limited sampling.